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TGFb acts as a tumor suppressor in normal epithelial cells and early-stage tumors and becomes an
oncogenic factor in advanced tumors. The molecular mechanisms involved in the malignant function
of TGFb are not fully elucidated. We demonstrate that high TGFb-Smad activity is present in aggres-
sive, highly proliferative gliomas and confers poor prognosis in patients with glioma. We discern the
mechanisms and molecular determinants of the TGFb oncogenic response with a transcriptomic
approach and by analyzing primary cultured patient-derived gliomas and human glioma biopsies.
The TGFb-Smad pathway promotes proliferation through the induction of PDGF-B in gliomas with
an unmethylated PDGF-B gene. The epigenetic regulation of the PDGF-B gene dictates whether
TGFb acts as an oncogenic factor inducing PDGF-B and proliferation in human glioma.INTRODUCTION
Tumors of glial origin, gliomas, are the most frequent pri-
mary tumors that arise in the brain. The most malignant
form of glioma, glioblastoma multiforme (grade IV), is
one of the most aggressive human cancers, with a median
survival of less than 1 year. Despite recent advances in
cancer biology, this statistic has not changed significantly
over the past years (Holland, 2001; Kleihues et al., 2002;
Maher et al., 2001; Sanai et al., 2005; Zhu and Parada,
2002).
Among other pathways, the TGFb pathway has been
implicated in glioma (Rich, 2003). TGFb is a multifunctional
cytokine that controls tissue homeostasis and embryonic
development. TGFb binds and activates a membrane re-Caceptor serine/threonine kinase complex, which phosphor-
ylates Smad2 and Smad3. Upon phosphorylation, Smads
accumulate in the nucleus, form transcriptional com-
plexes with Smad4 and other transcription factors, and
regulate transcription (Massague et al., 2005). In addition,
TGFb can signal through Smad-independent pathways
(Derynck and Zhang, 2003; Moustakas and Heldin,
2005). TGFb is a strong inhibitor of proliferation in epithelial
cells, astrocytes, and immune cells, and it is considered to
be a tumor suppressor factor. Some tumors acquire muta-
tions in elements of the TGFb pathway in order to escape
from the TGFb cytostatic response (Seoane, 2006). On the
other hand, some malignant tumors, including gliomas,
selectively lose the capacity of TGFb to inhibit proliferation
maintaining the TGFb pathway intact (Seoane, 2006). InSIGNIFICANCE
Glioma is the most common tumor of the brain, and its most malignant form, glioblastoma multiforme, is virtually
incurable. Despite recent advances, further study of the molecular mechanisms governing this malignancy is re-
quired in order to design successful therapeutic protocols based on rational molecular targeting. Our work dem-
onstrates that the TGFb-Smad pathway has a crucial role in glioma being a molecular marker of poor prognosis.
Furthermore, we identify the mechanisms and the molecular determinants of the oncogenic response to TGFb
in human glioma, showing that the induction of PDGF-B by TGFb and the epigenetic regulation of the PDGF-B
gene dictates the TGFb oncogenic function. This work provides biomarkers for patient stratification in anti-TGFb
therapies and identifies therapeutic targets against this disease.ncer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 147
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The TGFb Oncogenic Response in Gliomathose cases, TGFb can act as an oncogenic factor, and
it can induce proliferation, angiogenesis, invasion, and
metastasis as well as suppress the antitumoral immune
response. Thus, TGFb has a dual role in oncogenesis,
and depending on the type and stage of the tumor, it
can act as a tumor suppressor or a tumor promoter factor
(Derynck et al., 2001; Siegel and Massague, 2003). The
oncogenic role of TGFb has prompted the development
of therapeutic strategies based on the inhibition of the
TGFb pathway (Arteaga, 2006; Dumont and Arteaga,
2003; Yingling et al., 2004). The understanding of the
mechanisms that mediate the malignant transformation
of TGFb will improve the development of rational and
successful therapeutic strategies.
Little is known about the mechanisms involved in the
switch of the TGFb response toward malignancy. In a pre-
vious report, we have shown that the loss of the TGFb anti-
proliferative response in glioma is in part due to the in-
ability of TGFb to induce p21Cip1 when the PI3K-AKT
pathway is hyperactive and FoxG1 is expressed (Seoane
et al., 2004). However, not much is known about the
mechanisms responsible for the oncogenic function of
TGFb once the antiproliferative response is lost. PDGF-B
is a polypeptide that can dimerize and form homodimers
or heterodimers with PDGF-A. PDGF-BB and PDGF-AB
are potent mitogens and angiogenic factors that inter-
act with two tyrosine kinase receptors (PDGFRa and
PDGFRb) (Fredriksson et al., 2004). PDGF-B has been
clearly implicated in gliomagenesis (Dai et al., 2001; Guo
et al., 2003; Ostman, 2004). Our results show that TGFb
promotes glioma cell proliferation through the induction
of PDGF-B in tumors with an unmethylated PDGF-B
gene. The methylation status of the PDGF-B gene is
what determines the ability of TGFb to induce PDGF-B
and proliferation, and hence an oncogenic response in
human glioma.
RESULTS
A Hyperactive Smad Pathway Correlates with High
Proliferation and Poor Prognosis in Glioma
In order to analyze the activity of the TGFb pathway in gli-
oma, we determined the levels of p-Smad2 in a collection
of 52 patient-derived biopsies of astrocytomas of different
grades obtained from surgical resections (Table 1). We
decided to assess the cellular levels of p-Smad2 as an in-
dicator of the TGFb activity because Smad2 is the sub-
strate of the TGFb receptor I kinase (TbRI), and hence
phosphorylated Smad2 levels correlate with the intensity
of the TGFb signal received by the cell. Immunohisto-
chemical (IHC) analysis of the 52 tumors showed that
p-Smad2 was mainly localized in the nucleus and that
the intensity of the staining was variable depending on
the tumor sample (Figure 1A; Table 1). Total Smad2 levels
were not significantly different between tumor samples
(Figure 1A; Table 1). We determined the levels of TGFb
family members that can induce Smad2 phosphorylation
(TGFb1, TGFb2, TGFb3, Activin A, and Nodal) in 37 sam-
ples from our collection of 52 tumors (Table 1; Figure S1148 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier Inin the Supplemental Data available with this article online).
A significant correlation was observed between p-Smad2
levels and TGFb2 (p < 0.001; coef. 0.660; n = 37) and
TGFb3 (p < 0.001; coef. 0.459; n = 37). No correlation
was observed between p-Smad2 and the other ligands
assessed (Table 1; Figure S1). This indicates that high ex-
pression of TGFb2 and TGFb3 can account for the in-
creased levels of p-Smad2 observed in tumors. Ki67
levels were also analyzed in adjacent slides in order to de-
termine the proliferation rate of the glioma cells (Figure 1A;
Table 1). p-Smad2 and Ki67 levels were plotted against
each other, and a statistical analysis using the Spear-
man’s correlation test showed a significant correlation
between these parameters (p < 0.001) (Figure 1B). These
results suggested that TGFb could play a causal role in
the induction of proliferation. Consistently, some reports
have already described that TGFb can be an inducer of
cell proliferation in glioma cell lines (Piek et al., 1999;
Rich et al., 1999).
We obtained a well-documented medical history of
a subgroup of 25 patients with different tumor grades
and treatments who were diagnosed after January 2000
and had a complete surgical resection to be able to ac-
curately determine the time to progression (Table 1). The
25 patients were divided into two groups based on the
p-Smad2 levels found on their tumor biopsies. Tumors
from 13 patients expressed high levels of p-Smad2
(histo-score [H score] higher than the median of p-
Smad2 H scores, 110), while 12 patients had a p-Smad2
H score equal to or lower than 110. Progression-free
and overall survival curves were estimated by the Ka-
plan-Meier method and compared with the two-sided
log-rank test (Figures 1C and 1D). A significant difference
was observed in progression-free (p = 0.0015) and overall
survival (p = 0.012) between patients whose tumors had
high levels of p-Smad2 and those whose tumors did not.
These data indicate that a hyperactive TGFb-Smad path-
way is a poor prognosis factor.
Gliomas are classified into four grades based on his-
tological criteria set by the World Health Organization
(WHO), and glioma grade is a predictor of tumor prognosis
(Kleihues et al., 2002). As expected, p-Smad2 levels cor-
related with glioma grade (Figure S2), suggesting that
the TGFb-Smad pathway has an important role in glioma
progression and is a molecular biomarker that could be
used as an alternative predictor of disease outcome.
Effect of TGFb on Glioma Cell Proliferation
In order to study the effect of TGFb on glioma cell prolifer-
ation, we studied a panel of nine different glioma cell lines.
The screen was performed taking advantage of an inhibi-
tor of the TbRI, LY2109761 (Eli Lilly). This highly selective
compound acts as an ATP-binding competitor. We first
determined the dose of LY2109761 needed for the com-
plete inhibition of the TbRI kinase activity. As Smad2 is
the substrate of the TbRI kinase, we determined the min-
imal dose of LY2109761 required for the suppression of
p-Smad2 levels. In U87MG and U373MG cell lines,
a dose of 2 mM was enough to completely abolish thec.
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The TGFb Oncogenic Response in GliomaTable 1. Characteristics of the Patients
AA, anaplastic astrocytoma; FA, fibrillary astrocytoma; GBM, glioblastoma; PA, pilocytic astrocytoma; CR, complete resection;
PR, partial resection; S, surgery; Ct, chemotherapy; Rt, radiotherapy; T, temozolomide.induction of p-Smad2 by 200 pM TGFb (Figure S3). Next,
we performed a BrdU incorporation assay with the panel
of nine glioma cell lines treated with TGFb and/or 2 mM
LY2109761 in order to determine the effect of TGFb on
cell-cycle progression. Glioma cell lines were classified
in two groups depending on whether TGFb induced prolif-
eration (U373MG, A172, C4) or whether TGFb inhibited orCdid not have any major effect on proliferation (U87MG,
T98G, C3, C52, hs683, U251) (Figure 2A). Previous reports
using some of those cell lines agreed with our results (Piek
et al., 1999; Rich et al., 1999). In all the cell lines tested, the
TbRI inhibitor blocked the TGFb response and did not
have a major effect on proliferation when assayed in iso-
lation (Figure 2A).ancer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 149
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The TGFb Oncogenic Response in GliomaFigure 1. Effect of the TGFb-Smad Path-
way in Human Glioma Proliferation
(A) Immunohistochemical staining of human
glioma sections derived from patients 1, 4,
and 23 (Table 1) using p-Smad2, Smad2, or
Ki67 antibodies. Scale bar, 100 mm.
(B) Correlation between the levels of p-Smad2
and Ki67 (n = 52; p < 0.001, two-tailed Spear-
man test coefficient: 0.757).
(C and D) Kaplan-Meier estimates of time to
progression and overall survival. Differences
between patients with high p-Smad2 (H score
p-Smad2 >110) and low p-Smad2 (H score
p-Smad2 % 110) were highly significant (p =
0.0015 and p = 0.012) by log-rank test in time-
to-progression and overall survival curves,
respectively.We decided to focus on two cell lines in which TGFb had
opposed effects, U373MG and U87MG. We performed
a BrdU incorporation assay treating the cells with increas-
ing amounts of TGFb for 20 hr, and we blocked TGFb sig-
naling with the LY2109761 compound or a neutralizing
antibody against TGFb (Figure 2B). TGFb increased or
decreased BrdU incorporation in a dose-dependent man-
ner in U373MG cells and U87MG cells, respectively, and
the effect of TGFb was blocked by either the TbRI inhibitor
or the TGFb-neutralizing antibody. In addition, cells were
treated with TGFb and/or LY2109761 and counted after
72 hr. TGFb increased the number of U373MG cells and
decreased the number of U87MG cells (Figure S4). The
TbRI inhibitor blocked the TGFb effect on both cell lines
and did not affect cell proliferation when tested in isolation
(Figure S4).
Mediators of TGFb-Induced Proliferation
We next decided to discern the mechanism of the induc-
tion of proliferation by TGFb in glioma. TGFb was able to
induce proliferation in three of the nine glioma cell lines
tested. Moreover, the induction of proliferation by TGFb
was dependent on the TbRI activity because the TGFb ef-
fect was blocked by LY2109761. In order to identify which
TGFb responses mediate the induction of proliferation,
we compared the TGFb-responsive genes of U373MG
cells (where TGFb induces proliferation) and U87MG
cells (where TGFb inhibits proliferation) (see Figure 2A).
U373MG and U87MG cell lines were treated with TGFb,
LY2109761, or a combination of both for 3 hr to detect
the TGFb responses that are rapid and hence more likely
to be direct. RNA was extracted from those cells, and
a transcriptomic analysis using U133A plus Affymetrix mi-
croarrays was performed. We focused on the gene re-
sponses regulated by TGFb that were blocked by the
presence of TbRI inhibitor. We obtained 78 and 87 gene
responses to TGFb in U373MG and U87MG cells, respec-
tively, that were dependent on the TbRI activity. Consis-150 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier Intent with what has been previously reported (Piek et al.,
1999; Rich et al., 1999; Seoane et al., 2004), p21Cip1
and c-Myc were not regulated by TGFb in U373MG and
U87MG cell lines (see Figure 2D). The p15Ink4b gene is
deleted in both cell lines (Rich et al., 1999). This indicates
that the TGFb cytostatic response program is lost in
U373MG and U87MG cell lines. Comparing the gene re-
sponses to TGFb in U373MG and U87MG, we observed
63 gene responses specific for U373 cells; 15 genes
were common between U373MG and U87MG, and 72
genes were specific for U87MG (Figure 2C; Table 2). Inter-
estingly, most of the 15 common TGFb-responsive genes
were previously described to be regulated by TGFb in ep-
ithelial cells (Kang et al., 2003). This fact validated our ap-
proach and the transcriptomic analysis. We carefully ana-
lyzed the 63 gene responses to TGFb that were specific for
U373MG cells looking for genes that could explain the in-
crease in proliferation observed in TGFb-treated U373MG
cells. Six genes from the U373MG-specific responses
were described to be involved in cell proliferation using
the Gene Ontology description of molecular functions (Ta-
ble 2). From those six genes, PDGF-B stood out. PDGF-B
is a well-known factor that has already been shown to be
involved in glioma progression and has been implicated in
the TGFb-proliferative function (Dai et al., 2001; Fredriks-
son et al., 2004; Ostman, 2004).
We first validated that PDGF-B mRNA levels were in-
duced by TGFb in U373MG and not in U87MG using RT-
PCR (Figure 2D). We also validated 13 other genes, includ-
ing the five remaining gene responses classified as related
to cell proliferation by Gene Ontology and p21Cip1 and c-
Myc as part of the TGFb cytostatic response (Figure 2D).
We checked whether TGFb induced the secretion of the
PDGF-BB and PDGF-AB ligands using an ELISA assay.
Indeed, U373MG cells treated with TGFb secreted
much more PDGF-BB and PDGF-AB compared to
U87MG (Figure 2E). The secreted PDGF-BB and PDGF-
AB were functional, as we detected an increase in thec.
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The TGFb Oncogenic Response in GliomaFigure 2. Mediators of the TGFb Prolifer-
ative Response
(A) Cells from the indicated human glioma cell
lines were serum deprived and treated with
100 pM TGFb (black bars), 2 mM TbRI inhibitor
(gray bars), or both (white bars) for 20 hr, and
a BrdU incorporation assay was performed.
Results are represented as the percentage
change from control (DMSO-treated cultures).
All data are represented as the mean ± SD
from three independent experiments. (*p <
0.05, **p < 0.001).
(B) U373MG and U87MG cells were treated
with increasing doses of TGFb, 2 mM of TbRI
inhibitor, 2 mg/ml of TGFb1-neutralizing anti-
body, and an IgG control antibody as indi-
cated, and a BrdU incorporation assay was
performed. Results are represented as in (A).
(C) Venn diagram representing data obtained
from the microarray analysis of gene expres-
sion profiles of serum-starved U373MG and
U87MG cells treated for 3 hr with 100 pM
TGFb and/or 2 mM LY2109761.
(D) U373MG and U87MG cells were treated
with 100 pM TGFb and/or 2 mM LY2109761
for 3 hr in serum-free media, and the levels of
the indicated transcripts were determined by
RT-PCR. b-actin was determined as a loading
control.
(E) Levels of PDGF-BB/AB were determined by
an ELISA assay in conditioned media from
U373MG and U87MG cells treated or un-
treated with TGFb for 72 hr.
(F) U373MG and U87MG cells were treated
with 100 pM TGFb or 20 mM recombinant
PDGF-BB in serum-free media. Proliferation
was determined by a BrdU incorporation assay
20 hr after treatment. Results are expressed as
in (A).phosphorylation of the PDGF receptor in U373MG treated
with TGFb. Yet, in U87MG, the PDGF receptor remained
unphosphorylated upon TGFb addition (Figure S5). We
next confirmed that the PDGF-B pathway was functional
in both cell lines, since recombinant PDGF-BB was able
to induce proliferation in U373MG and U87MG cells
(Figure 2F).
Role of PDGF-B as a Mediator of the Induction
of Proliferation by TGFb
We next assessed whether PDGF-B was also induced by
TGFb in other glioma cell lines. We screened the panel of
nine glioma cell lines and found that PDGF-B was induced
by TGFb in four of them, U373MG, A172, C4, and C52
(Figure 3A). Either PDGFRa or PDGFRb was expressed
in all the cell lines tested, indicating that the TGFb-induced
PDGF-B had appropriate receptors available to transduce
the signal (Figure 3A). To determine whether the TGFb
pathway was functional, we determined the induction of
p-Smad2 levels and the TGFb target genes PAI-1 and
Smad7 by TGFb. Indeed, TGFb increased p-Smad2 levels
and induced either PAI-1 or Smad7 in all the cell lines
tested (Figure 3A).COur data showed a strong relationship between the
induction of PDGF-B and the proliferative response to
TGFb (Figure 3A and Figure 2A). In U373MG, A172, and
C4, TGFb induced both proliferation and PDGF-B tran-
scription. In C52 cells, TGFb induced PDGF-B but had
no effect on proliferation. Recombinant PDGF-BB was
not able to induce proliferation in C52 cells (data not
shown), indicating that the PDGF-BB pathway is not
functional in those cells.
We decided to assess whether the induction of prolifer-
ation by TGFb was mediated by PDGF-B. For this pur-
pose, we used a neutralizing antibody against PDGF-B
to specifically block the effect of the secreted PDGF-BB
and PDGF-AB in TGFb-treated cells. U373MG cells
were treated with TGFb, recombinant PDGF-BB, and/or
anti-PDGF-BB for 72 hr, and then an MTT assay was
performed to determine the number of viable cells. The
neutralizing antibody against PDGF-B decreased both
the TGFb- and the recombinant PDGF-BB-mediated in-
duction of proliferation in U373MG cells, and it did not af-
fect cell proliferation when assayed in isolation (Figure 3B).
We used another approach to discern the effect of PDGF-
B on TGFb-treated cells. We generated cell lines derivedancer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 151
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The TGFb Oncogenic Response in GliomaTable 2. TGFb-Responsive Genes in U373MG and U87MG Cells
U373MG and U87MG cells were treated with TGFb and/or the TbRI inhibitor for 3 hr, and then total RNA was subjected to Affymetrix
analysis with the U133-A plus microarray. Arrows indicate whether TGFb induced or repressed gene expression.from U373MG that constitutively expressed a short-hair-
pin RNA targeting PDGF-B. The TGFb-induced PDGF-B
mRNA as well as PDGF-BB/AB ligands were greatly di-
minished in two U373MG cell lines that expressed two in-
dependent short-hairpin RNAs, U373 sh1-PDGF-B and
U373 sh2-PDGF-B (Figures 3C and 3D). When cell prolif-
eration was assayed, the induction of proliferation by
TGFb was partially blocked in the cell lines that expressed
sh1-PDGF-B and sh2-PDGF-B (Figure 3E). Altogether,
these results indicated that PDGF-B is one of the main
mediators of the induction of proliferation by TGFb in
U373MG cells.
STI571 (Gleevec, Novartis) is a potent inhibitor of PDGF
kinase receptors as well as of Abl kinase and the c-Kit ki-
nase receptor (Druker, 2004). To complement and corrob-
orate our previous results, we used STI571 as a tool to as-
sess the effect of an inhibition of the PDGF receptor on
TGFb-induced proliferation. In order to determine the
dose of STI571 to be used in our experiments, we first152 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier Incperformed a dose-response experiment of STI571 in
U373MG cells treated or untreated with PDGF-BB. Addi-
tion of STI571 in isolation inhibited U373MG cell prolifera-
tion in a dose-dependent manner. Moreover, the lowest
concentration of STI571 that repressed the induction of
proliferation mediated by 20 nM recombinant PDGF-BB
was 5 mM (Figure S6). We decided to assess whether
5 mM STI571 could suppress TGFb-induced proliferation
in U373MG cells. We first observed that 5 mM STI571 pre-
vented the phosphorylation of the PDGF receptor in re-
sponse to TGFb and to recombinant PDGF-BB. Thus,
STI571 inhibited the activation of the PDGF receptor by
TGFb (Figure 3F). STI571 was able to decrease cell prolif-
eration when assayed in isolation despite that in untreated
U373MG cells the PDGF receptor is not phosphorylated
and hence not active (Figures 3F and 3G). This suggested
that STI571 was acting by PDGF receptor-independent
mechanisms in untreated U373MG cells. However,
STI571 inhibited the TGFb-mediated induction of.
Cancer Cell
The TGFb Oncogenic Response in GliomaFigure 3. PDGF-B Mediates TGFb-Induced Proliferation in
Glioma Cells
(A) The indicated nine human glioma cells lines were left untreated or
treated with 100 pM TGFb for 3 hr in serum-free media, and the levels
of PDGF-B, PDGFRa, PDGFRb, PAI-1, Smad7, and b-actin mRNA
were determined by RT-PCR analysis. p-Smad2 and Smad2 were de-
termined by immunoblotting in cells treated under the same conditions.
(B) Number of viable cells was determined using an MTT assay in
U373MG cells after a 72 hr treatment with 1 ng/ml of PDGF-B-neutral-
izing antibody and/or 100 pM TGFb or 20 mM recombinant PDGF-BB
in 0.2% serum media. Results are represented as the percentage
change from control (untreated cells). All data represent the mean ±
SD from three experiments (*p < 0.05).
(C and D) RNA interference was used to specifically knock down TGFb-
induced PDGF-B in U373MG. Polyclonal cell cultures stably express-
ing sh1-PDGF-B, sh2-PDGF-B, or a control vector (control) were
treated with 100 pM TGFb for 3 hr; RNA was harvested; and PDGF-B
mRNA levels were determined by RT-PCR analysis. b-actin expression
was used for normalization. Alternatively, serum-starved cells were
treated with 100 pM TGFb for 72 hr, and levels of PDGF-BB/AB were
analyzed by ELISA in the conditioned media.
(E) U373MG-TH (control), U373MG-sh1-PDGF-B, and U373MG-sh2-
PDGF-B cells were treated with 100 pM TGFb for 72 hr in 0.2% serum
media. Number of viable cells was determined by an MTT assay, and
results were expressed as the percentage change from control (DMSO-
treated cells). All data represent the mean ± SD from three experiments.
(F) U373MG cells were pretreated with 5 mM STI571 for 2 hr and treated
with either 100 pM TGFb or 20 mM of recombinant PDGF-BB for a fur-Caproliferation due to its effect on the PDGF receptor (see
Figure 3F), and moreover, the combination of TGFb and
STI571 inhibited proliferation to a greater extent than
STI571 in isolation. This suggested that, in the presence
of STI571, TGFb had an antiproliferative response in
U373MG cells (Figure 3G). In order to identify the mecha-
nism that mediates this antiproliferative effect, we ana-
lyzed the regulation of genes involved in cell-cycle arrest
(p21Cip1, p27Kip1, and c-Myc) as well as Smad7 and
PAI-1. Interestingly, an increase in p21Cip1 levels was de-
tected in cells treated with TGFb and STI571 and could
explain the antiproliferative effect of the combination of
TGFb and STI571 (Figure S7).
Mechanisms of the Differential Activation of PDGF-B
in Response to TGFb
Our results showed that TGFb promotes proliferation via
the induction of PDGF-B expression in certain glioma
cells. Still, we did not know why TGFb was able to induce
PDGF-B in some glioma cells but not in others. In order to
address this issue, we decided to discern the molecular
mechanisms involved in the activation of PDGF-B tran-
scription by TGFb. First, we assessed whether the induc-
tion of PDGF-B by TGFb in U373MG was direct or required
new protein synthesis. TGFb induced PDGF-B in the pres-
ence of cycloheximide, an inhibitor of RNA translation, in-
dicating that the transactivation of PDGF-B by TGFb did
not require the synthesis of other factors (Figure 4A). Other
reports have shown that Smads can bind and transacti-
vate the proximal region of the PDGF-B promoter in endo-
thelial cells and macrophages (Taylor and Khachigian,
2000; Chow et al., 2005). To determine whether Smads
were also involved in the induction of PDGF-B in glioma
cells, we knocked down Smad2, Smad3, Smad2 and -3,
and Smad4 using RNA interference and determined
whether PDGF-B induction by TGFb was affected. The in-
duction of PAI-1 by TGFb was also analyzed as an
experimental control. Indeed, Smad2, Smad3, and Smad4
were required for PDGF-B induction by TGFb, since
PDGF-B levels were decreased when any of the Smads
were downregulated in the presence of TGFb (Figure 4B).
We also performed a chromatin immunoprecipitation as-
say (ChIP) and observed that endogenous Smad2 or -3
bound the proximal PDGF-B promoter in response to
TGFb in U373MG cells but not in U87MG (Figure 4C).
Smads did not bind to a distal promoter region of the
PDGF-B gene (Figure 4C). The fact that Smads did not in-
teract with the PDGF-B promoter in U87MG could explain
why PDGF-B was not induced by TGFb in those cells.
ther 3 hr. Equal amounts of protein were subjected to immunopre-
cipitation using an anti-PDGFR antibody and immunoblotting using
antibodies against phospho-tyrosine (upper panel) and PDGFR (lower
panel).
(G) U373MG cells were treated with 100 pM TGFb, 5 mM STI571, and
20 mM of recombinant PDGF-BB in 0.2% serum media for 72 hr as
indicated, and cells were counted. Results are expressed as the per-
centage change from control (untreated cells). All data represent the
mean ± SD from three experiments.ncer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 153
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The TGFb Oncogenic Response in GliomaFigure 4. Methylation of the PDGF-B Gene Blocks the Induction of PDGF-B by TGFb
(A) U373MG cells were treated for 16 hr with cycloheximide (CHX) and then treated with 100 pM TGFb for a further 3 hr. mRNA levels of PDGF-B and
b-actin were determined by RT-PCR analysis.
(B) RT-PCR analysis to determine PDGF-B, PAI-1, and b-actin levels, and immunoblotting using specific antibodies against Smad2/3, Smad4, or
a-tubulin were performed in U373MG cells treated with 100 pM TGFb for 3 hr after siRNA-mediated knockdown of Smad2, Smad3, Smad2, and
Smad3 or Smad4 as indicated.
(C) U373MG and U87MG cells were treated with 100 pM TGFb for 3 hr, and ChIP assays were performed with the indicated antibodies and the
indicated PCR primers.
(D) U87MG cells were transfected with the396/+84 PDGF-B luciferase reporter, treated with 100 pM TGFb or 0.2 mM TPA for 20 hr and analyzed for
luciferase activity.
(E) U373MG and U87MG were left untreated or treated with 50 mM 5-aza-dC for 3 days and then treated with 100 pM TGFb or 0.2 mM TPA for 3 hr.
PDGF-B and b-actin mRNA levels were determined by RT-PCR analysis.
(F) Distribution of CpG islands in the 400/+1000 PDGF-B promoter region. Arrow represents the transcription start site. Determination of the
methylation status of CpG sites by sequencing of bisulfite-modified DNA. Circles represent the CpG sites present in the +342/+372 PDGF-B promoter
region (methylated black circles, unmethylated open circles).
(G) Methylation status of the PDGF-B gene in U373MG and U87MG cells determined by methylation-specific PCR assay. M, methylated;
U, unmethylated.Strikingly, TGFb was able to transactivate the 396/+84
PDGF-B luciferase reporter in U87MG cells (Figure 4D).
Moreover, TPA, a well-known inducer of PDGF-B in endo-
thelial cells (Jin et al., 1993), activated the PDGF-B lucifer-
ase reporter more than 5-fold (Figure 4D). Interestingly,
both TPA and TGFb did not induce endogenous PDGF-
B transcription in U87MG cells (Figure 4E). The fact that
TGFb and TPA induced the PDGF-B reporter but not the
endogenous PDGF-B gene in U87MG cells suggested
that there was a regulation of the PDGF-B gene at the level
of the chromatin structure. Thus, we hypothesized that the
PDGF-B promoter was silenced by methylation in U87MG
cells and not in U373MG. Indeed, using a bioinformatic
approach, we observed that the 50UTR of the PDGF-B
gene contained two CpG islands (see Figure 4F). Inhibition
of methylation with an inhibitor of DNA methyltrans-154 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier Inferases, 5-aza-20-deoxycytidine (5-aza-dC), facilitated
the induction of endogenous PDGF-B by TGFb and
TPA in U87MG, indicating that DNA methylation could
be blocking the TGFb-mediated induction of PDGF-B
(Figure 4E). Consistently, Smad2/3 bound the proximal
PDGF-B promoter in response to TGFb in U87MG cells
treated with 5-aza-dC (Figure S8). In addition, U87MG
cells treated with the 5-aza-dC lost the partial antiprolifer-
ative effect of TGFb in a dose-dependent manner, indicat-
ing that the rescue of the induction of PDGF-B could
antagonize the antiproliferative response to TGFb (Fig-
ure S9). Sequencing of bisulfite-modified DNA showed
that one of the CpG islands of the 50UTR of PDGF-B
was highly methylated in U87MG compared to U373MG
(Figure 4F). In addition, we developed a methylation-
specific PCR (MSP) assay and confirmed the bisulfitec.
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and PDGF-B Induction in Primary
Cultured Tumor Biopsies
(A) Serum-deprived primary cultured tumor
cells (PCTC 1–10) were treated with 100 pM
TGFb alone or in combination with 2 mM TbRI
inhibitor for 20 hr. BrdU incorporation was
measured and is expressed as the percentage
change from control (DMSO-treated cultures).
All data are represented as the mean ± SD of
triplicate experiments. (*p < 0.05, **p < 0.001).
(B) PCTCs were left untreated or treated with
100 pM TGFb for 3 hr in serum-free media
and subjected to RT-PCR analysis to detect
the mRNA levels of the indicated genes.
(C) Methylation status of the PDGF-B gene in
PCTCs 2-10 determined by methylation-
specific PCR assay.
(D) PDGF-B, p-Smad2, and Ki67 levels were
determined by IHC in the nine human gliomas
from which we obtained PCTCs. Scale bar,
100 mm.
(E) Quantification of PDGF-B, p-Smad2, and
Ki67 levels determined in (D).sequencing results (Figure 4G). Altogether, these results
showed that methylation of the PDGFB gene prevents
the induction of PDGFB by TGFb in U87MG cells.
The TGFb Proliferative Response, PDGF-B
Induction, and Methylation of the PDGF-B
Gene in Patient-Derived Gliomas
Established cell lines have been in culture for a long time
adapting to grow in artificial conditions and diverging
from the original tumor cells (Lee et al., 2006). We decided
to analyze the TGFb proliferative response in cells from
human gliomas grown in culture for a very short period
of time, hence, with characteristics similar to the cells
present in the tumor mass (Lee et al., 2006). Therefore,
we extended our studies to primary cultured tumor cells
(PCTCs) from patient-derived glioma biopsies. Tumor
cells from ten different gliomas of diverse grades were
seeded less than half an hour after tumor resection, and
in less than three to five passages we obtained enough
cells to perform a cell proliferation assay. Cells were
left untreated or treated with TGFb or with TGFb plus theCTbRI inhibitor, and a BrdU incorporation assay was
performed. TGFb induced proliferation in four PCTCs, de-
creased proliferation in two PCTCs, and had no major ef-
fect on the rest of the PCTCs (Figure 5A). In all cases, the
TbRI inhibitor blocked the TGFb effect, indicating that the
effect of TGFb on proliferation was dependent on the TbRI
activity. In addition, the levels of PDGF-B, PDGFRa/b, and
PAI-1 transcripts were analyzed by RT-PCR. PDGFRa
or -b was expressed in all PCTCs. Moreover, PAI-1 was
induced by TGFb, indicating that the TGFb pathway was
functional in the PCTCs (Figure 5B). We observed that
only four PCTCs induced PDGF-B in response to TGFb.
Interestingly, those four PCTCs were the same ones in
which TGFb induced proliferation (Figures 5A and 5B).
Our results showed that the capacity of TGFb to induce
proliferation coincided with its ability to induce PDGF-B
both in PCTCs as well as in glioma cell lines. Moreover,
we analyzed the methylation status of the PDGF-B gene
of PCTCs 2–10 using the MSP assay and bisulfite-treated
DNA sequencing in order to assess whether methylation
was responsible for the lack of the PDGF-B induction byancer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 155
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The TGFb Oncogenic Response in GliomaFigure 6. The Methylation Status of the
PDGF-B Gene Accounts for the Lack of
PDGF-B Expression in Human Glioma
(A) p-Smad2 and Smad2/3 protein levels and
PDGF-B, Smad7, PAI-1, and 18S mRNA levels
were determined in the human gliomas from
which we obtained PCTC 6–10 using immuno-
blotting and RT-PCR analysis, respectively.
(B) Methylation status of the PDGF-B gene in
tumors from PCTCs 6–10 determined by meth-
ylation-specific PCR assay and sequencing of
bisulfite-modified DNA. (Black circles repre-
sent CpG sites found methylated in more
than a 50% of ten sequenced clones.)
(C) Correlation between the levels of p-Smad2
and PDGF-B (n = 52; p < 0.001, two-tailed
Spearman test coefficient: 0.729).
(D) Methylation status of the 21 tumors ex-
pressing low levels of PDGF-B (H score <
100) determined by methylation-specific PCR
assay of paraffin sections. M, methylated; U,
unmethylated.
(E) In gliomas that are not aggressive and have
low levels of proliferation, the induction of
PDGF-B by TGFb is impaired due to methyla-
tion of the PDGF-B promoter, and the TGFb-
Smad pathway is poorly active. On the other
hand, in highly aggressive and proliferative gli-
omas, the PDGF-B gene is not methylated,
PDGF-B is induced by TGFb, and the TGFb-
Smad pathway is hyperactive.TGFb. Three (PCTCs 2, 4, and 8) of the six PCTCs in which
TGFb did not induce PDGF-B had a methylated gene in-
dicating that the lack of TGFb-mediated PDGF-B trans-
activation is due to epigenetic silencing (Figure 5C;
Figure S10). Still other unknown mechanisms besides
methylation are preventing the induction of PDGF-B by
TGFb in PCTCs 3, 5, and 10. As expected, none of the
PCTCs in which TGFb induced PDGF-B had a methylated
PDGF-B gene. Moreover, neither normal human neuro-
progenitors, human fetal astrocytes, nor human fetal neu-
rons had a methylated PDGF-B gene (Figure S10).
Next, we decided to analyze the tumor samples that
generated the PCTCs. The levels of p-Smad2, PDGF-B,
and Ki67 were analyzed by IHC in paraffin sections of
the tumors that generated the PCTCs except for PCTC 3
due to lack of sample. As expected from our results in Fig-
ure 1, p-Smad2 levels correlated with Ki67 levels. Interest-
ingly, PDGF-B levels also correlated with p-Smad2 levels.
Moreover, high levels of p-Smad2, PDGF-B, and Ki67
were detected in those tumors in which TGFb induced
cell proliferation and not in the others (Figures 5A, 5D,
and 5E). We then determined the p-Smad2 and total
Smad2 levels of the tumors that generated PCTCs 6, 7,
8, 9, and 10 by immunoblotting and observed that in the
tumors that generated the PCTCs in which TGFb was
not inducing proliferation (PCTCs 8 and 10), p-Smad2
levels were low, corroborating and validating the IHC re-
sult (Figure 6A). In addition, PDGF-B, Smad7, and PAI-1
RNA levels were analyzed by RT-PCR, and the expression
of all three TGFb target genes was also low in those tu-156 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier Incmors that generated PCTCs 8 and 10 (Figure 6A). In order
to address whether the epigenetic regulation of the PDGF-
B gene was involved in the lack of PDGF-B expression, we
determined the methylation status of the PDGF-B gene
sequencing of bisulfite-modified DNA and MSP assay in
the tumor samples. The tumor that expressed the lowest
levels of PDGF-B and had low p-Smad2 levels (tumor of
PCTC 8) had its promoter methylated (Figure 6B). This
agrees with the results of the PDGF-B methylation status
of PCTC 8 (see Figure 5C and Figure S10).
We finally analyzed the levels of PDGF-B in the collec-
tion of 52 astrocytomas by IHC and checked whether
high levels of PDGF-B correlated with high levels of p-
Smad2. Indeed, that was the case, and a strong and sig-
nificant correlation (p < 0.001) was observed between
PDGF-B levels and p-Smad2 levels (Figure 6C). Moreover,
we asked whether methylation of the PDGF-B gene was
responsible for the lack of expression of PDGF-B in the
collection of astrocytoma samples. We analyzed those as-
trocytomas with low expression of PDGF-B (H score <
100), 21 tumors, using the MSP assay and found that
around 50% of them (ten tumors) had a highly methylated
PDGF-B gene (Figure 6D). Interestingly, only one of the ten
tumors with a methylated PDGF-B gene had high levels of
p-Smad2, indicating that there is not a selective pressure
during tumor progression to acquire a hyperactive TGFb-
Smad pathway when the PDGF-B gene is methylated.
In summary, tumors with low TGFb-Smad activity and
low PDGF-B levels were the ones that generated PCTCs
in which TGFb did not induce proliferation, and vice versa,.
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levels generated PCTCs in which TGFb induced PDGF-B
and proliferation. Thus, when TGFb acts as a proliferative
factor by inducing PDGF-B, it favors glioma progression
and provides a selective advantage for tumor progression,
and the tumor tends to acquire a hyperactive TGFb-Smad
pathway. In addition, the methylation of the PDGF-B gene
accounts for the inability of TGFb to induce PDGF-B tran-
scription and hence proliferation in a large proportion of
human gliomas, and tumors do not acquire a hyperactive,
oncogenic TGFb-Smad pathway when the PDGF-B gene
is methylated.
DISCUSSION
Recent advances in the understanding of the molecular
mechanisms that govern oncogenesis have provided
meaningful progress in the treatment of many common
human cancers. Still, much more has to be done in order
to improve present therapeutic approaches. Malignant gli-
oma is one of the most aggressive human cancers, and
treatment strategies for this disease have only increased
survival slightly (Holland, 2001; Maher et al., 2001; Zhu
and Parada, 2002). Among several other pathways,
TGFb has been implicated in glioma (Rich, 2003). In
normal epithelial cells, TGFb is a potent inhibitor of prolif-
eration, and it has been considered a tumor suppressor.
During tumor progression, however, the TGFb antiprolifer-
ative function is lost, and in certain cases TGFb becomes
an oncogenic factor inducing cell proliferation, invasion,
angiogenesis, and immune suppression (Derynck et al.,
2001; Siegel and Massague, 2003). Recently, we and
others have begun to unveil the mechanisms through
which TGFb loses its antiproliferative response in glioma
(Seoane, 2006). However, not much is known about how
TGFb promotes tumorigenesis.
We have focused our work on the study of the oncogenic
role of TGFb in glioma. We found that a high p-Smad2 level
is a poor prognostic marker, supporting that TGFb is acting
as an oncogenic factor in glioma and has an important role
in glioma progression. Moreover, this indicates that p-
Smad2 is a molecular biomarker of disease outcome in gli-
oma. The significant correlation observed between p-
Smad2 levels and the levels of TGFb2 and TGFb3 in human
tumors indicates that high expression of these two ligands
can be responsible for the increased activity of the TGFb-
Smad pathway. In addition, the fact that there is a good
correlation between p-Smad2 levels and Ki-67 in human
glioma suggested that TGFb is involved in human glioma
cell proliferation. Indeed, we found that TGFb induces pro-
liferation in some glioma cell lines as it was reported (Piek
et al., 1999; Rich et al., 1999). Comparing the TGFb gene
responses of two cell lines (U373MG and U87MG) where
TGFb has opposed effects on proliferation, we found 63
genes that could be involved in TGFb-mediated induction
of proliferation. Among those genes, we focused on
PDGF-B due to its known role in carcinogenesis. Indeed,
PDGF-B was induced whenever TGFb activated prolifera-
tion. Moreover, blockade of the PDGF-B function (usingCaneutralizing antibodies, RNA interference, or inhibitors of
the PDGF receptor) prevented TGFb-dependent induction
of proliferation. Moreover, in primary cultured tumor cells,
PDGF-B was induced whenever TGFb induced prolifera-
tion. Consistently, in a collection of 52 gliomas, we found
that high p-Smad2 levels strongly correlated with high
levels of PDGF-B. These results strongly suggested that
PDGF-B is a mediator of the proliferative response to
TGFb in glioma.
TGFb induced PDGF-B in some gliomas but not in
others. In order to assess what determined the induction
of PDGF-B by TGFb, we pursued the study of the molec-
ular mechanisms involved in the PDGF-B transcriptional
activation by TGFb. RNA interference and chromatin
immunoprecipitation experiments demonstrated that
PDGF-B transactivation is mediated by an activated
Smad complex that binds to the proximal promoter of
PDGF-B. Interestingly, Smad2 or -3 did not bind to the
proximal promoter of PDGF-B in U87MG in response to
TGFb, even though TGFb activated transcription of a re-
porter construct containing the proximal region of the
PDGF-B promoter. This inconsistency could be explained
by the chromatin structure of the endogenous PDGF-B
gene and, more specifically, could be due to the epige-
netic regulation of the PDGF-B gene. Treatment with
methyltransferase inhibitors and sequencing of bisulfite-
modified DNA demonstrated that the 50UTR of the
PDGF-B gene had methylated CpG islands in U87MG
cells. Moreover, around 50% of human gliomas with low
PDGF-B expression have a methylated PDGF-B gene, in-
dicating that epigenetic silencing accounts for the lack of
PDGF-B induction by TGFb and therefore for the inability
of TGFb to induce glioma cell proliferation in a large pro-
portion human gliomas. Several years ago, PDGF was
suggested to be involved in the response to TGFb of three
hyperdiploid glioma cell lines (Jennings et al., 1997), al-
though other studies failed to find this link (Piek et al.,
1999; Rich et al., 1999). Our results demonstrate that the
proliferative response to TGFb in human glioma is medi-
ated by the induction of PDGF-B and is dictated by the
methylation status of the PDGF-B gene.
In many cases, cancer progression is favored by hyper-
methylation of the promoter of tumor suppressors. Our
results showed that lack of methylation of a specific gene
facilitates TGFb-induced proliferation and oncogenesis. To
date there is only one other similar and recently published
observation. Hypomethylation of the Pax2 gene facilitates
tamoxifen-induced endometrial carcinogenesis showing,
as in our case, that hypomethylation of a specific gene
can be involved in tumor progression (Wu et al., 2005).
In neuroprogenitor cells, the PDGF-B promoter is not
methylated. This suggests that the presence of an unme-
thylated PDGF-B gene in certain tumors is a characteristic
that resembles the neuroprogenitor state and that methyl-
ation of the PDGF-B gene observed in some tumors might
be due to a process of cell differentiation or to an aberrant
epigenetic regulation. This is an ongoing subject of study.
The involvement of the Smad-dependent or Smad-
independent pathways in TGFb-promoted oncogenesisncer Cell 11, 147–160, February 2007 ª2007 Elsevier Inc. 157
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Dumont and Arteaga, 2003). Our present work argues
that a Smad-dependent signaling through the induction
of PDGF-B has a proliferative and oncogenic role in gli-
oma. High levels of p-Smad2 are present in highly prolifer-
ative and aggressive tumors when TGFb is able to induce
PDGF-B and proliferation. On the other hand, those tu-
mors where TGFb is not able to induce PDGF-B and pro-
liferation, mostly due to methylation of the PDGF-B gene,
do not have high levels of TGFb activity and tend not to be
aggressive. Moreover, tumors with a methylated PDGF-B
gene do not present a hyperactive TGFb-Smad pathway
(Figure 6E). This might be due to the fact that the induction
of PDGF-B by TGFb favors glioma progression, providing
a selective advantage to the tumor cell, and allowing the
tumor to acquire a hyperactive TGFb-Smad pathway. In
contrast, tumors with a methylated PDGF-B gene do not
tend to acquire a hyperactive TGFb-Smad pathway, since
TGFb is then unable to act as an oncogenic factor. In ad-
dition, the fact that PDGF-B mediates the TGFb prolifera-
tive response suggests that blocking PDGF-B function, for
example with PDGF receptor inhibitors such as STI571,
might prevent the TGFb oncogenic function.
Due to its oncogenic role, the TGFb pathway is being
evaluated as a therapeutic target (Arteaga, 2006; Dumont
and Arteaga, 2003; Yingling et al., 2004). The potential role
of TGFb inhibitors on angiogenesis, immune surveillance,
and EMT, in addition to their ability to block PDGF-B in-
duction and thus proliferation, suggests a promising ther-
apeutic benefit of such compounds. The dual and com-
plex role of TGFb in oncogenesis presents a unique
challenge that has to be addressed to be able to select
the patient population that may benefit from an anti-
TGFb therapy. The understanding of the exact mecha-
nisms involved in the malignant transformation of TGFb
will improve patient stratification and the development of
successful therapeutic strategies as well as provide ther-
apeutic targets to restore normal TGFb function.
EXPERIMENTAL PROCEDURES
Cell Lines and Primary Cultured Tumor Cells
U87MG, U373MG, A172, and T98G were obtained from American
Type Culture Collection. hs683 and U251 were obtained from
D. Bigner. C3, C4, and C52 were obtained from J. Cowell. All cell lines
were cultured in DMEM with 10% fetal bovine serum (FBS). Fresh brain
tumor tissues obtained from both Vall d’Hebron and Sant Joan de De´u
Hospitals were collected and processed within 30 min after resection.
The clinical protocol was approved by the Vall d’Hebron IRB (CEIC)
with informed consent obtained from all subjects. The primary cultured
tumor cells were obtained after mechanical dissociation according to
the technique previously described (van Beusechem et al., 2002).
Briefly, tumor tissue was cut into pieces of 1–5 mm3 and plated in
a 60 mm2 tissue culture dish with DMEM with 10% FBS and antibiotics.
Additionally and in parallel, minced pieces of tumor were incubated
with 200 U/ml collagenase I (Sigma) and 500 U/ml DNaseI (Sigma) in
PBS during 1 hr at 37C with vigorous constant agitation as previously
described (Joshi et al., 2000). The single-cell suspension was filtered
through a 70 mm cell strainer (BD Falcon), washed with PBS, and sus-
pended in DMEM-10% FBS. Cell cultures were subsequently split 1:2
when confluent and experiments were done before passage 3–5.158 Cancer Cell 11, 147–160, February 2007 ª2007 Elsevier IncMicroarray Expression Analysis
RNA was harvested from U373MG and U87MG cell lines treated as in-
dicated. Three independent experiments were performed. Five micro-
grams of extracted total RNA was used to generate biotinylated com-
plementary RNA (cRNA) following the standard Affymetrix GeneChip
protocol. Each sample was hybridized with an Affymetrix Human Ge-
nome U133A microarray at the Vall d’Hebron Research Institute Geno-
mics facility. CEL files were imported into the ArrayAssist package
(Stratagene) and preprocessed using the RMA (robust multiarray anal-
ysis) algorithm with the default parameters. Genes were filtered ac-
cording to the following criterion: AbsFC with respect to their respec-
tive control experiments R 2. Genes complying with these criteria
were then used for later study. The microarray data have been submit-
ted to the European Bioinformatics Institute (EBI) public database
(accession number E-MEXP-903).
Immunohistochemistry
Tumor biopsies were obtained from patients with histological diagno-
sis of glioblastoma, anaplastic astrocytoma, fibrillary astrocytoma, and
pilocytic astrocytoma according to the World Health Organization
(Kleihues et al., 2002). Informed consent was obtained prospectively,
and tissue collection was approved by each Institutional Review
Board. Fresh tumor samples were collected from primary tumors un-
der surgery. Samples were fixed immediately after removal in a 10%
buffered formalin solution for a maximum of 48 hr at room temperature
before being dehydrated and paraffin embedded under vacuum. Areas
of representative tumor, away from necrotic foci, were identified on
a hematoxylin-eosin-stained section, three 0.6 mm cores were taken
from separate areas, and each one was arrayed into recipient blocks
in a 1 mm-spaced grid. The following antibodies were used for the de-
tection of proteins: anti-PDGF-B (H55 rabbit polyclonal antibody,
Santa Cruz Biotech) (Lou et al., 2004; Toda et al., 1999), anti-Ki67
(clone MIB1, Dako), and anti-p-Smad2 (clone 138D4, Cell Signaling
Tech) (Kang et al., 2005). The specificity of the staining with anti-
PDGF-B and anti-p-Smad2 antibodies was controlled using other an-
tibodies, preincubating the antibody with the antigen, and performing
immunoblotting of glioma extracts (Figure S11). To score a tumor cell
as positive, cytoplasmic staining was required for PDGF-B, and
nuclear staining was required for Ki67 and p-Smad2. For quantitative
analysis of PDGF-B, p-Smad2, and Smad2, the percentage of stained
tumor cells and intensity of staining were evaluated in representative
high-power fields (3400) on tissue sections using optical microscopy.
The result was expressed as a H score ranged 0–300 and calculated as
the percentage of weakly stained cells plus the percentage of moder-
ately stained cells multiplied by two plus the percentage of strongly
stained cells multiplied by three. For Ki67, the percentage of tumor-
stained cells was calculated in representative microscopic fields.
Scoring was performed blind to clinical data and was used for statisti-
cal analysis.
Statistical Analysis
Overall and progression-free survival curves were estimated by the
Kaplan-Meier method and compared with the use of the two-sided
log-rank test. Time of tumor recurrence was established from the
time of surgery to the date when recurrence was detected. Overall sur-
vival was measured from the date of surgical resection to the last fol-
low-up visit or death. Patients without tumor recurrence or alive at the
end of follow-up were censored. A Spearman correlation test was used
to analyze relationships between the following pairs of parameters:
TGFb ligands and p-Smad2, Ki67 and p-Smad2, and PDGF-B and
p-Smad2. An ANOVA test was used to analyze tumor grade and
p-Smad2. Data in bar graphs are expressed as the mean ± SD.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and eleven supplemental figures and can be found with
this article online at http://www.cancercell.org/cgi/content/full/11/2/
147/DC1/..
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